Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/24021
Title: | An open label phase II study evaluating first-line EGFR tyrosine kinase inhibitor erlotinib in non-small cell lung cancer patients with tumors showing high EGFR gene copy number | Authors: | Szutowicz-Zielinska, Ewa Konopa, Krzysztof Kowalczyk, Anna Suszko-Kazarnowicz, Malgorzata Duchnowska, Renata Szczesna, Aleksandra Ratajska, Magdalena Sowa, Aleksander Limon, Janusz Biernat, Wojciech BURZYKOWSKI, Tomasz Jassem, Jacek Dziadziuszko, Rafal |
Issue Date: | 2017 | Publisher: | IMPACT JOURNALS LLC | Source: | ONCOTARGET, 8(10), p. 17270-17278 | Abstract: | Background: First-line treatment with epidermal growth factor receptor (EGFR) inhibitors in NSCLC is effective in patients with activating EGFR mutations. The activity of erlotinib in patients harboring high EGFR gene copy number has been considered debatable. Patients and Methods: A multicenter, open-label, single-arm phase II clinical trial was performed to test the efficacy of erlotinib in the first-line treatment of NSCLC patients harboring high EGFR gene copy number defined as >= 4 copies in >= 40% of cells. Findings: Between December 2007 and April 2011, tumor samples from 149 subjects were screened for EGFR gene copy number by fluorescence in-situ hybridization (FISH), Out of 49 patients with positive EGFR FISH test, 45 were treated with erlotinib. Median PFS in the intent-to-treat population was 3.3 months (95% CI: 1.8-3.9 months), and median overall survival was 7.9 months (95% CI: 5.1-12.6 months). Toxicity profile of erlotinib was consistent with its known safety profile. The trial was stopped prematurely at 63% of originally planned sample size due to accumulating evidence that EGFR gene copy number should not be used to select NSCLC patients to first-line therapy with EGFR TKI. Data on erlotinib efficacy according to EGFR, KRAS and BRAF mutations are additionally presented. Interpretation: This trial argues against using high gene copy number for selection of NSCLC patients to first-line therapy with EGFR TKIs. The study adds to the discussion on efficacy of other targeted agents in patients with target gene amplified tumors. | Notes: | [Szutowicz-Zielinska, Ewa; Konopa, Krzysztof; Kowalczyk, Anna; Jassem, Jacek; Dziadziuszko, Rafal] Med Univ Gdansk, Dept Radiotherapy & Oncol, Gdansk, Poland. [Suszko-Kazarnowicz, Malgorzata] Ctr Pulm Dis Olsztyn, Dept Oncol, Olsztyn, Poland. [Duchnowska, Renata] Mil Inst Med, Dept Oncol, Warsaw, Poland. [Szczesna, Aleksandra] Mazovian Ctr Treatment Lung Dis & TB, Dept Lung Dis, Otwock, Poland. [Ratajska, Magdalena; Limon, Janusz] Med Univ Gdansk, Dept Biol & Genet, Gdansk, Poland. [Sowa, Aleksander] Roche, Warsaw, Poland. [Biernat, Wojciech] Dept Med Univ Gdansk, Gdansk, Poland. [Burzykowski, Tomasz] Hasselt Univ, Interuniv Inst Biostatist & Stat Bioinformat, Diepenbeek, Belgium. | Keywords: | non-small cell lung cancer; epidermal growth factor receptor; gene copy number; erlotinib;non-small cell lung cancer; epidermal growth factor receptor; gene copy number; erlotinib | Document URI: | http://hdl.handle.net/1942/24021 | ISSN: | 1949-2553 | DOI: | 10.18632/oncotarget.13793 | ISI #: | 000396024600094 | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2018 |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
13793-205915-5-PB (1).pdf | Published version | 1.69 MB | Adobe PDF | View/Open |
SCOPUSTM
Citations
2
checked on Sep 2, 2020
WEB OF SCIENCETM
Citations
2
checked on Sep 28, 2024
Page view(s)
60
checked on Sep 7, 2022
Download(s)
106
checked on Sep 7, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.